期刊文献+

自体外周血造血干细胞的采集和衡量 被引量:2

THE COLLECTION AND THE EVALUATION OF PERIPHERAL BLOOD STEM CELLS
下载PDF
导出
摘要 自体外周血造血干细胞(PBSC)移植后血液系统的重建与采集和保存的PBSC的质量和数量有密切关系。在15名病人的76次PBSC的采集和保存中,发现PBSC的质量和数量有明显的个体差异,与疾病的类型和化疗方案有密切关系。NHL中CD+34细胞与CFU-GM的比例平均为25%,CML为67%,MM最低为139%,这可能是因为MM病人的血清中存在白细胞分化的抑制因子。CML病人中CD+34/CD-33细胞在总的CD+34细胞中的比例很低,提示此类病人的早期造血干细胞很少。NICOOL程控降温仪与-80℃冰箱在细胞的冷冻保存中没有明显的差异。认为单一项目的检测不能全面评价BPSC的质量和数量,应该同时进行单个核细胞计数、CFU-GM数和CD+34细胞数的评估。 The quality and quantity of peripheral blood stem cells (PBSC) are considered as an essential factor for short term and long term hematopoietic reconstruction after PBSC autograft. In 15 patients, 76 apheresis were taken. We found that the quality and quantity of PBSC were different and depend on the type of diseases and the intensity of chemotherapy. The ratio between CD + 34 cells and CFU GM was 25% in Non Hodgkin`s Lymphoma, 67% in Chronic Myelogenous Leukemia and 139% in Multiple Myloma. The lowest ratio was in Multiple Myeloma, it was probably because there was inhibitor in serum of Multiple Myeloma. The CD + 34 /CD - 33 cells in total CD + 34 cells were low for Chronic Myelogenous Leukemia and suggested that few immature stem cell existed in PBSC of CML. The PBSC freezing with the method between Nicool freezer and -80℃ refrigerator was not different. The result demonstrated that only one test was not enough for measure of quality and quantity of BPSC. It is necessary that CFU GM, rate of CD + 34 cells and numbers of MNC be evaluated together.
出处 《白血病》 1997年第3期136-139,共4页
关键词 外周血 造血干细胞 采集 衡量 移植 PBSCA PBSC Collection Evaluation
  • 相关文献

同被引文献19

  • 1罗斌,王文治.脂肪乳剂对淋巴细胞免疫功能的影响[J].肠外与肠内营养,1995,2(1):43-45. 被引量:2
  • 2姜铭,娄海玲,李炳臣.粒细胞性白血病患者外周血T细胞亚群系统分布的研究[J].白血病,1996,5(3):166-167. 被引量:8
  • 3LOBATO - MENDIZABAL E, RUIZ - ARGUELLES GJ,MARIN- LOPEZ A. Malnutrition is an adverse prognostic factor of the outcome of treatment of patients with standard- risk acute lymphoblastic leukaemia [J]. LeukRes, 1989, 13 (10): 899.
  • 4HENON PH. Peripheral blood cell transplantation: past,present and future [J]. Stem Cell, 1993, 11: 154.
  • 5BENDER JG, TO LB, WILLIAMS S, et al. Defining a therapeutic dose of peripheral blood stem cells [J]. JHematother, 1992, 1 (4): 329.
  • 6GOLDSCHMIDT H,HEGENBART U,WALLMEIER M,et al.Hish—dose therapy with peripheral blood progeniton cell[J].Ann Oncol,1997,8(3):243.
  • 7ZIEGLER TR,YOUNG LS,BENFEUⅨ,et al.Clinicaland metablolc efficacy of glutamine—supplemented parenteral nutrition after bone marrow transplantation[J].Ann Imem Med.1992.116:821.
  • 8HAYLOCK DN,SIMMONS PJ,JUTTNER CA.The biology and clinical USeS of blood stem cell[J].Blood,1997,89(7):2233.
  • 9Mollee P, Pereira D, Nagy T, et al. Cyclophosphamide,etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant, 2002,30:273-278.
  • 10Milone G, Leotta S, Indelicato F, et al. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: result depend on degree of previous pretreatment. Bone Marrow Treatment, 2003,31:747-754.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部